Repurposing Lopinavir (ABT-378): Insights from FDA Drug Screening Against MERS-CoV

Study Background and Research Question

The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 presented a critical challenge to public health, with a high fatality rate and no approved antivirals for treatment. Rapidly escalating case numbers and the absence of a known animal reservoir intensified concerns about possible global spread, reminiscent of the 2003 SARS outbreak. In this context, de Wilde et al. (reference study) sought to identify existing drugs with anti-MERS-CoV activity that could be rapidly transitioned to clinical application.

Key Innovation from the Reference Study

The primary innovation of the study was a systematic, cell-based screening of a 348-compound library of FDA-approved drugs to identify molecules capable of inhibiting MERS-CoV replication. By focusing on repurposing clinically established compounds, the researchers addressed the urgent need for immediate therapeutic options against emerging viral threats—circumventing the lengthy timelines associated with novel drug development. Notably, the screen identified Lopinavir (ABT-378), a well-characterized HIV protease inhibitor, as one of four compounds with significant anti-MERS-CoV effects in vitro.

Methods and Experimental Design Insights

The screening process was structured to maximize translational relevance and reproducibility. Key aspects include:

• Compound Library Selection: The authors curated a panel of 348 FDA-approved drugs, ensuring all candidates had established safety profiles in humans.
• Cell Culture Assay: Vero E6 cells were infected with MERS-CoV and treated with each compound. Viral replication was measured via immunofluorescence targeting the viral nucleocapsid protein.
• Hit Identification Criteria: Compounds were advanced based on their ability to reduce viral replication by >50% at non-cytotoxic concentrations. Dose-response experiments established EC50 and CC50 values, enabling calculation of selectivity indices.
• Cross-Virus Comparison: The antiviral activity of identified hits was further validated against SARS-CoV and human coronavirus 229E, providing a broader assessment of spectrum.

Protocol Parameters

• Dose-Response Testing: Typical EC50 values for Lopinavir against MERS-CoV were in the low micromolar range (3–8 μM), as determined by immunofluorescence-based quantification (reference study).
• Cytotoxicity Assessment: Parallel cell viability assays were performed to exclude non-specific toxic effects, with selectivity index thresholds guiding hit progression.
• Viral Load Measurement: Viral antigen quantification was performed at 48 hours post-infection, reflecting compound effects on a single replication cycle.
• Control Conditions: DMSO was used as a vehicle control; untreated and mock-infected cells provided baseline and assay validation checkpoints.

Core Findings and Why They Matter

The screen identified four compounds—chloroquine, chlorpromazine, loperamide, and Lopinavir (ABT-378)—that robustly inhibited MERS-CoV replication in vitro. Lopinavir demonstrated low micromolar EC50 values, indicating potent antiviral activity. Importantly, all four compounds also inhibited replication of SARS-CoV and human coronavirus 229E, suggesting broad-spectrum potential. The data imply that partial reduction in viral load, even without complete inhibition, could provide a clinically meaningful window for immune response development in acute infections, as argued in the reference study.

Lopinavir’s identification is particularly noteworthy due to its established role in HIV therapy and its biochemical properties, such as strong protease inhibition and favorable serum protein binding characteristics. This cross-pathogen efficacy supports the rationale for leveraging existing HIV protease inhibitors in coronavirus outbreak response—a translational bridge confirmed by the study’s results.

Comparison with Existing Internal Articles

Internal resources, such as “Lopinavir Identified as MERS-CoV Inhibitor via FDA Drug Screen,” corroborate the reference study’s finding of Lopinavir as a candidate for MERS-CoV inhibition. Other internal summaries, including “Lopinavir (ABT-378): Unleashing Precision HIV Protease In...” and “Lopinavir (ABT-378): Potent HIV Protease Inhibitor Facts,” provide detailed mechanistic context for Lopinavir’s established use in HIV protease inhibition assays and resistance studies. These articles emphasize the compound’s picomolar activity against both wild-type and mutant HIV protease, high efficacy in serum-containing conditions, and its critical role in HIV infection research and antiretroviral therapy development.

The cross-domain application of Lopinavir, as documented in the reference study, aligns with the internal perspective that compounds with robust biochemical profiles in one viral system may offer rapid-response solutions in another, especially when timeframes for de novo drug development are prohibitive.

Limitations and Transferability

While the identification of Lopinavir and other agents as MERS-CoV inhibitors is promising, several limitations must be considered. The study’s findings are based on in vitro assays using immortalized cell lines, which do not recapitulate the complexity of human immune responses, pharmacokinetics, or tissue distribution. The concentrations required for antiviral activity in vitro may not be achievable or safe in patients, or may differ significantly in in vivo contexts. Furthermore, the study did not assess combination effects or address potential resistance mechanisms in coronaviruses, which could impact long-term efficacy.

Translating these findings into clinical practice requires additional work in animal models and, ultimately, controlled human trials. The reference authors themselves note that observed antiviral effects may serve to reduce viral load sufficiently to enable an effective host immune response, rather than achieving sterilizing immunity. As such, Lopinavir and similar agents should be considered as candidates for adjunctive, rather than standalone, therapy pending further evidence (reference study).

Why this cross-domain matters, maturity, and limitations

The cross-domain identification of Lopinavir, a potent HIV protease inhibitor, as an inhibitor of MERS-CoV replication underscores the strategic value of repurposing antiviral agents with favorable pharmacological and safety profiles. This approach can accelerate the deployment of therapeutic interventions during emerging infectious disease outbreaks, where rapid response is critical. However, clinical translation remains a challenge due to differences in viral targets, host cell tropism, and the complexity of disease pathogenesis in vivo. The maturity of this strategy is currently limited by the paucity of clinical efficacy data in coronavirus infections, highlighting the need for rigorous follow-up studies.

Research Support Resources

To support experimental workflows similar to those described in the reference study, researchers can utilize Lopinavir (ABT-378, SKU A8204) from APExBIO, a compound with validated potency in HIV protease inhibition and documented cross-pathogen relevance. Its robust activity profile, including resistance to serum protein effects and effectiveness against protease mutants, makes it suitable for HIV drug resistance studies, HIV infection research, and exploratory antiviral screening in cell-based assays. Researchers are advised to consult the product information regarding solubility, storage, and handling to ensure experimental integrity.